Clover And 2 Other ASX Penny Stocks To Consider

The Australian market has shown resilience, with the ASX200 rising by 0.75% to 8,437 points, buoyed by positive developments such as China's measured response to tariffs and strong performances in the materials sector. In such a climate, investors often look beyond blue-chip stocks for opportunities that offer both growth and value potential. Penny stocks, though sometimes seen as a throwback to earlier trading days, remain relevant for those seeking companies with solid financials and hidden potential.

Top 10 Penny Stocks In Australia

Name	Share Price	Market Cap	Financial Health Rating
Embark Early Education (ASX:EVO)	A$0.79	A$141.28M	★★★★☆☆
LaserBond (ASX:LBL)	A$0.575	A$66.82M	★★★★★★
Austin Engineering (ASX:ANG)	A$0.50	A$310.07M	★★★★★☆
MaxiPARTS (ASX:MXI)	A$1.90	A$106.21M	★★★★★★
GTN (ASX:GTN)	A$0.535	A$105.06M	★★★★★★
Helloworld Travel (ASX:HLO)	A$1.94	A$322.38M	★★★★★★
SHAPE Australia (ASX:SHA)	A$3.00	A$247.9M	★★★★★★
IVE Group (ASX:IGL)	A$2.20	A$334.56M	★★★★☆☆
SKS Technologies Group (ASX:SKS)	A$1.59	A$235.35M	★★★★★★
Nickel Industries (ASX:NIC)	A$0.745	A$3.2B	★★★★★☆

Click here to see the full list of 1,032 stocks from our ASX Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Clover (ASX:CLV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Clover Corporation Limited produces, refines, and sells natural oils and encapsulated powders across Australia, New Zealand, Asia, Europe, the Middle East, and the Americas with a market cap of A$70.97 million.

Operations: The company generates revenue of A$62.21 million from its Nutritional Oil and Microencapsulated Powders segment.

Market Cap: A$70.97M

Clover Corporation Limited, with a market cap of A$70.97 million, operates in the nutritional oil and encapsulated powders segment, generating A$62.21 million in revenue. Despite its experienced management team and board, Clover has faced challenges with negative earnings growth over the past year (-75.6%) and declining profits over five years (24.1% annually). However, it maintains strong financial health with more cash than total debt and well-covered interest payments by EBIT (3.5x coverage). The company's short-term assets significantly exceed both short-term and long-term liabilities, providing a solid liquidity position despite low profit margins (2.4%).

• Jump into the full analysis health report here for a deeper understanding of Clover.
• Examine Clover's earnings growth report to understand how analysts expect it to perform.

First Graphene (ASX:FGR)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: First Graphene Limited focuses on the research, development, mining, exploration, manufacture, and sale of graphene products in Australia and the United Kingdom with a market cap of A$41.54 million.

Operations: The company's revenue is derived from Graphene Production, which accounts for A$0.30 million, and Research & Development, contributing A$0.19 million.

Market Cap: A$41.54M

First Graphene Limited, with a market cap of A$41.54 million, is pre-revenue, generating less than US$1 million annually from its graphene production and R&D activities. The company remains unprofitable but has been reducing losses over the past five years. Despite having more cash than total debt and short-term assets exceeding liabilities, First Graphene's cash runway is limited to less than a year if free cash flow grows at historical rates. Its board is experienced with an average tenure of 4.3 years, though management experience data is insufficient for assessment. Shareholders have not faced significant dilution recently.

• Navigate through the intricacies of First Graphene with our comprehensive balance sheet health report here.
• Gain insights into First Graphene's past trends and performance with our report on the company's historical track record.

Touch Ventures (ASX:TVL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Touch Ventures Limited is a private equity and venture capital firm focusing on growth capital for high-growth, post-revenue, and later-stage companies, with a market cap of A$53.84 million.

Operations: The company generates revenue through operating and managing investments in high-growth securities, amounting to A$38.07 million.

Market Cap: A$53.84M

Touch Ventures Limited, with a market cap of A$53.84 million, is pre-revenue, generating less than US$1 million annually. Despite being unprofitable and having negative return on equity (-46.05%), the company maintains a stable financial position with no debt and short-term assets (A$59.3M) exceeding liabilities (A$239K). It has sufficient cash runway for over three years if free cash flow continues to grow at historical rates. The board is experienced with an average tenure of 4.8 years, though management experience data is insufficient for assessment. Shareholders have not faced significant dilution recently despite earnings declines over five years.

• Get an in-depth perspective on Touch Ventures' performance by reading our balance sheet health report here.
• Explore historical data to track Touch Ventures' performance over time in our past results report.

Turning Ideas Into Actions

• Unlock more gems! Our ASX Penny Stocks screener has unearthed 1,029 more companies for you to explore.Click here to unveil our expertly curated list of 1,032 ASX Penny Stocks.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com